Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market

Product Saw Zero Sales Since April Approval

 
• By Mandy Jackson
  
Beqvez was the last gene therapy left in Pfizer's portfolio (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Advanced Therapies